Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Schuind

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Vaccine|June 9, 2006
Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 yearsSteven Black, Leonard R Friedland, Anne Schuind, et al.
The Journal of Infectious Diseases|February 28, 2015
Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized TrialAnne Schuind, Nathan Segall, Mamadou Drame, et al.
Journal of Pediatric Gastroenterology and Nutrition|August 21, 2004
Intestinal imaging of children with acute rotavirus gastroenteritisDorsey Bass, Eileen Cordoba, Cornelia Dekker, et al.
Vaccine|December 5, 2020
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipientsJosephine Ocran-Appiah, Céline Boutry, Caroline Hervé, et al.
Pediatrics|April 3, 2002
Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infantsFred Zepp, Anne Schuind, Claudius Meyer, et al.
Rheumatology (Oxford, England)|September 10, 2020
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trialsAlemnew F Dagnew, Debora Rausch, Caroline Hervé, et al.
Vaccine|November 9, 2024
Evidence for an HPV one-dose scheduleMargaret Stanley, Anne Schuind, Kirthini K Muralidharan, et al.
The Journal of Infectious Diseases|February 28, 2020
The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster VaccineAlemnew F Dagnew, Nicola P Klein, Caroline Hervé, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 19, 2009
Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young womenHelen Trottier, Salaheddin M Mahmud, Lisa Lindsay, et al.
Vaccine|April 26, 2015
Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled studyPatricia Izurieta, Woo Joo Kim, Seong-Heon Wie, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Vaccine|June 9, 2006
Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 yearsSteven Black, Leonard R Friedland, Anne Schuind, et al.
The Journal of Infectious Diseases|February 28, 2015
Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized TrialAnne Schuind, Nathan Segall, Mamadou Drame, et al.
Journal of Pediatric Gastroenterology and Nutrition|August 21, 2004
Intestinal imaging of children with acute rotavirus gastroenteritisDorsey Bass, Eileen Cordoba, Cornelia Dekker, et al.
Vaccine|December 5, 2020
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipientsJosephine Ocran-Appiah, Céline Boutry, Caroline Hervé, et al.
Pediatrics|April 3, 2002
Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infantsFred Zepp, Anne Schuind, Claudius Meyer, et al.
Rheumatology (Oxford, England)|September 10, 2020
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trialsAlemnew F Dagnew, Debora Rausch, Caroline Hervé, et al.
Vaccine|November 9, 2024
Evidence for an HPV one-dose scheduleMargaret Stanley, Anne Schuind, Kirthini K Muralidharan, et al.
The Journal of Infectious Diseases|February 28, 2020
The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster VaccineAlemnew F Dagnew, Nicola P Klein, Caroline Hervé, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 19, 2009
Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young womenHelen Trottier, Salaheddin M Mahmud, Lisa Lindsay, et al.
Vaccine|April 26, 2015
Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled studyPatricia Izurieta, Woo Joo Kim, Seong-Heon Wie, et al.
Pageof 6